Novel Illumina-based next generation sequencing approach with one-round amplification provides early and reliable detection of BCR-ABL1 kinase domain mutations in chronic myeloid leukemia.
BCR-ABL1
TKI resistance
illumina
kinase domain mutation
next generation sequencing
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
30
07
2019
accepted:
16
10
2019
pubmed:
11
2
2020
medline:
2
2
2021
entrez:
11
2
2020
Statut:
ppublish
Résumé
The occurrence of mutations in the BCR-ABL1 kinase domain (KD) can lead to treatment resistance in chronic myeloid leukaemia patients. Nowadays, next-generation sequencing (NGS) is an alternative method for the detection of kinase domain mutations, compared to routinely used Sanger sequencing, providing a higher sensitivity of mutation detection. However, in the protocols established so far multiple rounds of amplification limit reliable mutation detection to approximately 5% variant allele frequency. Here, we present a simplified, one-round amplification NGS protocol for the Illumina platform, which offers a robust early detection of BCR-ABL1 KD mutations with a reliable detection limit of 3% variant allele frequency.
Substances chimiques
Fusion Proteins, bcr-abl
EC 2.7.10.2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
469-474Subventions
Organisme : Ministry of Health
ID : 17-30397A
Pays : International
Informations de copyright
© 2020 British Society for Haematology and John Wiley & Sons Ltd.
Références
Arezi, B. & Hogrefe, H.H. (2007) Escherichia coli DNA polymerase III ε subunit increases Moloney murine leukemia virus reverse transcriptase fidelity and accuracy of RT-PCR procedures. Analytical Biochemistry, 360, 84-91.
Baccarani, M., Deininger, M.W., Rosti, G., Hochhaus, A., Soverini, S., Apperley, J.F., Cervantes, F., Clark, R.E., Cortes, J.E., Hjorth-Hansen, H., Hughes, T.P., Kantarjian, H.M., Kim, D., Larson, R.A., Lipton, J.H., Martinelli, G., Mayer, J., Martin, C.M., Steegmann, J., Goldman, J.M. & Hehlmann, R. (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood, 122, 872-884.
Baer, C., Kern, W., Koch, S., Nadarajah, N., Schindela, S., Meggendorfer, M., Haferlach, C. & Haferlach, T. (2016) Ultra-deep sequencing leads to earlier and more sensitive detection of the tyrosine kinase inhibitor resistance mutation T315I in chronic myeloid leukemia. Haematologica, 101, 830-838.
Deininger, M.W.N., Goldman, J.M., Lydon, N. & Melo, J.V. (1997) The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood, 90, 3691-3698.
Deininger, M.W., Hodgson, J.G., Shah, N.P., Cortes, J.E., Kim, D.W., Nicolini, F.E., Talpaz, M., Baccarani, M., Müller, M.C., Li, J., Parker, W.T., Lustgarten, S., Clackson, T., Haluska, F.G., Guilhot, F., Kantarjian, H.M., Soverini, S., Hochhaus, A., Hughes, T.P., Rivera, V.M. & Branford, S. (2016) Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients. Blood, 127, 703-712.
Erbilgin, Y., Eskazan, A.E., Hatirnaz Ng, O., Salihoglu, A., Elverdi, T., Firtina, S., Tasar, O., Mercan, S., Sisko, S., Khodzhaev, K., Ongoren, S., Ar, M.C., Baslar, Z., Soysal, T., Sayitoglu, M. & Ozbek, U. (2019) Deep sequencing of BCR-ABL1 kinase domain mutations in chronic myeloid leukemia patients with resistance to tyrosine kinase inhibitors. Leukemia & Lymphoma, 60, 200-207.
Eyal, E., Tohami, T., Amir, A., Cesarkas, K., Jacob-Hirsch, J., Volchek, Y., Nagler, A., Rechavi, G. & Amariglio, N. (2013) Detection of BCR-ABL1 mutations in chronic myeloid leukaemia by massive parallel sequencing. British Journal of Haematology, 160, 477-486.
Hochhaus, A., Kreil, S., Corbin, A.S., La Rosée, P., Müller, M.C., Lahaye, T., Hanfstein, B., Schoch, C., Cross, N.C.P., Berger, U., Gschaidmeier, H., Druker, B.J. & Hehlmann, R. (2002) Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia, 16, 2190-2196.
Kizilors, A., Crisà, E., Lea, N., Passera, R., Mian, S., Anwar, J., Best, S., Nicolini, F.E., Ireland, R., Aldouri, M., Pocock, C., Corbett, T., Gale, R., Bart-Smith, E., Weston-Smith, S., Wykes, C., Kulasekararaj, A., Jackson, S., Harrington, P., McLornan, D., Raj, K., Pagliuca, A., Mufti, G.J. & de Lavallade, H. (2019) Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based study. The Lancet Haematology, 6, e276-e284.
Machova Polakova, K., Kulvait, V., Benesova, A., Linhartova, J., Klamova, H., Jaruskova, M., de Benedittis, C., Haferlach, T., Baccarani, M., Martinelli, G., Stopka, T., Ernst, T., Hochhaus, A., Kohlmann, A. & Soverini, S. (2015) Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase. Journal of Cancer Research and Clinical Oncology, 141, 887-899.
Poláková, K.M., Polívková, V., Rulcová, J., Klamová, H., Jurček, T., Dvořáková, D., Žáčková, D., Pospíšil, Z., Mayer, J. & Moravcová, J. (2010) Constant BCR-ABL transcript level ≥0.1% (IS) in patients with CML responding to imatinib with complete cytogenetic remission may indicate mutation analysis. Experimental Hematology, 38, 20-26.
Potapov, V. & Ong, J.L. (2017) Examining sources of error in PCR by single-molecule sequencing. PLoS ONE, 12, e0169774.
Schmitt, M.W., Fox, E.J., Prindle, M.J., Reid-Bayliss, K.S., True, L.D., Radich, J.P. & Loeb, L.A. (2015) Sequencing small genomic targets with high efficiency and extreme accuracy. Nature Methods, 12, 423-425.
Soverini, S., De Benedittis, C., Polakova, K.M., Brouckova, A., Horner, D., Iacono, M., Castagnetti, F., Gugliotta, G., Palandri, F., Papayannidis, C., Iacobucci, I., Venturi, C., Bochicchio, M.T., Klamova, H., Cattina, F., Russo, D., Bresciani, P., Binotto, G., Giannini, B., Kohlmann, A., Haferlach, T., Roller, A., Rosti, G., Cavo, M., Baccarani, M. & Martinelli, G. (2013) Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain. Blood, 122, 1634-1648.
Soverini, S., De Benedittis, C., Polakova, K.M., Linhartova, J., Castagnetti, F., Gugliotta, G., Papayannidis, C., Mancini, M., Klamova, H., Salvucci, M., Crugnola, M., Iurlo, A., Albano, F., Russo, D., Rosti, G., Cavo, M., Baccarani, M. & Martinelli, G. (2016) Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients. Oncotarget, 7, 21982-21990.